Innate Pharma (XPAR:IPH) ROE % Adjusted to Book Value : -8.30% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma ROE % Adjusted to Book Value?

Innate Pharma's ROE % for the quarter that ended in Dec. 2023 was -33.85%. Innate Pharma's PB Ratio for the quarter that ended in Dec. 2023 was 4.08. Innate Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -8.30%.

Innate Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Innate Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma ROE % Adjusted to Book Value Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-5.00

-19.58

-12.19

-14.89

-3.50

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-14.67	6.40	-31.29	1.53	-8.30

Competitive Comparison of Innate Pharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Innate Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Innate Pharma's ROE % Adjusted to Book Value falls into.

Innate Pharma ROE % Adjusted to Book Value Calculation

Innate Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-14.28%	/	4.08
	=	-3.50%

Innate Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-33.85%	/	4.08
	=	-8.30%

Innate Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Innate Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines